Ovata Capital Management’s Global Blood Therapeutics, Inc. GBT Stock Holding History

Ovata Capital Management’s Portfolio GBT Stock Details GBT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-21,996	Closed	-$762K	–	199
2022 Q1	$762K	Sell	21,996 -3,768	-15%	-$113K	0.23%	28
2021 Q4	$754K	Buy	25,764 +10,764	+72%	+$333K	0.26%	27
2021 Q3	$382K	Buy	15,000 +4,500	+43%	+$132K	0.15%	28
2021 Q2	$368K	Buy	10,500 +3,000	+40%	+$117K	0.18%	32
2021 Q1	$306K	Buy	+7,500	New	+$345K	0.19%	35
2020 Q3	–	Sell	-2,160	Closed	-$136K	–	200
2020 Q2	$136K	Buy	+2,160	New	+$148K	0.04%	82

Other funds holding GBT

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

KCM

Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return

Ovata Capital Management's GBT Position: Q2 2022 in Review

Ovata Capital Management sold out of Global Blood Therapeutics, Inc. (GBT) in Q2 2022, closing a stake of 21,996 shares — an estimated $762K sold.

Ovata Capital Management first reported a position in GBT in Q2 2020 and held it in 6 quarters. The position peaked at $762K in Q1 2022. 195 funds tracked by Wall St. Rank hold GBT as of Q2 2022.

Ovata Capital Management reported no remaining Global Blood Therapeutics, Inc. position as of Q2 2022 after selling out during the quarter.
Ovata Capital Management sold 21,996 Global Blood Therapeutics, Inc. shares in Q2 2022, an estimated $762K.
Ovata Capital Management first reported a position in Global Blood Therapeutics, Inc. in Q2 2020 and held it in 6 quarters.
Ovata Capital Management's Global Blood Therapeutics, Inc. position peaked at $762K in Q1 2022.
195 funds tracked by Wall St. Rank held Global Blood Therapeutics, Inc. as of Q2 2022.

Based on Ovata Capital Management's 13F filing for Q2 2022, filed 5 Aug 2022.